Solazyme, Inc. Announces Proposed Offering of $100 Million of Convertible Senior Subordinated Notes
Solazyme, Inc. (NASDAQ: SZYM) announced today that it intends to offer,
subject to market and other considerations, $100 million aggregate
principal amount of Convertible Senior Subordinated Notes due 2018 (the
“Convertible Notes”) in a private placement under the Securities Act of
1933, as amended (the “Securities Act”). Solazyme also intends to grant
to the initial purchaser of the Convertible Notes a 30-day option to
purchase up to an additional $15 million aggregate principal amount of
the Convertible Notes solely to cover over-allotments. Solazyme intends
to use the net proceeds of the offering to fund project related costs
and capital expenditures and for general corporate purposes.
The Convertible Notes will be general unsecured obligations of Solazyme
and will be subordinated in right of payment to its Senior Debt (as
defined in the indenture governing the Convertible Notes). The
Convertible Notes will effectively rank junior in right of payment to
any of Solazyme’s secured indebtedness to the extent of the value of the
assets securing such indebtedness and be structurally junior to all
indebtedness and other liabilities of Solazyme’s subsidiaries, including
trade payables.
The Notes will be convertible into shares of the Company’s common stock,
par value $0.001 per share, at the then-applicable conversion rate until
the close of business on the scheduled trading day immediately preceding
maturity. The Notes will not be redeemable at the Company’s option prior
to maturity. The interest rate, conversion rate and other terms of the
Convertible Notes will be determined at the time of pricing of the
offering.
The offering is being made to qualified institutional buyers pursuant to
Rule 144A under the Securities Act. Neither the Convertible Notes nor
the shares of Solazyme’s common stock issuable upon conversion of the
Convertible Notes have been or are expected to be registered under the
Securities Act or under any state securities laws and, unless so
registered, may not be offered or sold in the United States or to U.S.
persons except pursuant to an exemption from, or in a transaction not
subject to, the registration requirements of the Securities Act and
applicable state securities laws. This press release does not constitute
an offer to sell or the solicitation of an offer to buy any securities,
nor shall it constitute an offer, solicitation or sale in any
jurisdiction in which such offer, solicitation or sale is unlawful.
About Solazyme, Inc.
Solazyme, Inc. (SZYM) is a renewable oil and bioproducts company that
transforms a range of low-cost plant-based sugars into high-value oils.
Headquartered in South San Francisco, Solazyme’s renewable products can
replace or enhance oils derived from the world’s three existing sources
– petroleum, plants and animal fats. Initially, Solazyme is focused on
commercializing its products into three target markets: (1) fuels and
chemicals, (2) nutrition and (3) skin and personal care.
Solazyme®, the Solazyme logo and other
trademarks or service names are trademarks of Solazyme, Inc.
Forward Looking Statements
This press release includes forward-looking statements regarding
Solazyme’s financing plans, including statements related to Solazyme’s
offering of the Convertible Notes and intended use of net proceeds of
the offering. Such statements are subject to certain risks and
uncertainties including, without limitation, risks related to whether
Solazyme will offer or consummate the offering of the Convertible Notes,
including whether Solazyme will be able to satisfy the conditions
required to close any sale of the Convertible Notes, market and other
general economic conditions, the actual or anticipated terms of the
Convertible Notes and the anticipated use of the net proceeds from any
sale of the Convertible Notes. Solazyme’s forward-looking statements
also involve assumptions that, if they never materialize or prove
correct, could cause its results to differ materially from those
expressed or implied by such forward-looking statements. Although
Solazyme’s forward-looking statements reflect the good faith judgment of
its management, these statements are based only on facts and factors
currently known by Solazyme. As a result, you are cautioned not to rely
on these forward-looking statements.
